Business Standard

Vaccine majors see sharp rally with some players rising more than 4,000%

The Indian pharmaceutical sector has also been going through a surge

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Premium

The difference in valuations between Indian and global players has also changed.

Sachin P Mampatta Mumbai
Global listed firms that may develop a vaccine for Covid-19 have seen a sharp rally from their lows in CY20. Some players have risen in excess of 4,000 per cent. They include firms such as Vaxart and Novavax. Moderna is up over 433 per cent from its January lows.

The Indian pharmaceutical sector has also been going through a surge. The Nifty Pharma Index is up over 80 per cent from the March lows. The difference in valuations between Indian and global players has also changed. The price-to-earnings ratio has fallen for players on a median basis. It was around 21.1

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in